Article
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells.
Scientific reports - 8 Nov 2016
Liu Xin, Wu Xiaosheng, Cao Siyu, Harrington Susan M, Yin Peng, Mansfield Aaron S, Dong Haidong
Abstract excerpt
B7-H1 (aka PD-L1) blocking antibodies have been used in treatment of human cancers through blocking B7-H1 expressed by tumor cells; however, their impact on B7-H1 expressing tumor-reactive CD8+ T cells is still unknown. Here, we report that tumor-reactive CD8+ T cells expressing B7-H1 are functional effector cells. In contrast to normal B7-H1 blocking antibody, B7-H1 antibodies capable of activating p38 MAPK lose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.